RxDoctor Payments Data

Jieming Yan, MD

Internal Medicine · Chesapeake, VANPI 1003814732

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 58 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$155
  • Pfizer$153
  • Novartis$114
  • Mylan Specialty L.p.$112
  • E.r. Squibb & Sons, L.L.C.$97
  • Boehringer Ingelheim$87
  • plus $447 from 14 others

What the payments were for

  • Food & beverage$1,12697%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$176,037
Medicare patients
421
Services billed
1,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$21,934
EntrestoSacubitril/Valsartan13$9,307
Breo ElliptaFluticasone/Vilanterol11$3,730
Pantoprazole Sodium49$766
Metoprolol Succinate49$664
Potassium Chloride32$463
Albuterol Sulfate HfaAlbuterol Sulfate14$323
Finasteride14$308
Ondansetron OdtOndansetron17$300
Escitalopram Oxalate16$260
Bumetanide11$235
Atorvastatin Calcium46$194
Amlodipine Besylate52$167
Furosemide29$141
Lisinopril18$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$21,93437 claims
NovartisEntresto$114$9,30713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →